Oura postpones Nasdaq IPO amid market uncertainty

Oura postponed its Nasdaq IPO, targeting $2.2B from 50M shares at $40-$44 each, valuing it at $15.62B. CEO Tom Hale cited market conditions. Oura reports 90% revenue growth expected for 2026, 5.7M paid members, and profitability. Investors like Eli Lilly and Dragoneer showed interest. Goldman Sachs, Morgan Stanley, and J.P. Morgan are underwriters.

Original reporting
Published Sep 29, 2026, 11:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 12:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oura postpones Nasdaq IPO amid market uncertainty — source image
Decision brief

The 30-second read

High
01

Why it matters

The postponement removes immediate supply of new shares, likely reducing short‑term volatility in related fintech and wearable stocks.

02

Market read

The delay underscores heightened sensitivity of IPO markets to macro‑economic headwinds, affecting investor appetite for new listings.

03

What to watch

Oura's strong revenue growth and profitability could attract renewed interest once market conditions improve.

Relevance 8/10Novelty 8/10Timing: today

Background

Oura, a health‑monitoring wearable maker, had filed for a Nasdaq IPO targeting a $15.6 B valuation but postponed the offering due to market uncertainty.

Market effects

IPO postponement may signal broader weakness in tech listings amid rate uncertainty.

Potential dampening effect on US Nasdaq new‑issue pipeline and related fintech investors.

Highlights macro‑driven slowdown in capital markets affecting both US and European issuers.

Counterpoint

Some investors may view the delay as a temporary pause, positioning for a later, potentially higher‑priced offering.

Key entities

  • Oura

    Finnish health‑tech firm planning a Nasdaq IPO.

  • Goldman Sachs

    Lead underwriter for Oura's planned IPO.

Related articles

Med

Nelson Advisors: Strategic Patent Litigation in the Wearables Market - Analysis of Oura Ring v UltraHuman and SVTronics

Ouraring Inc. sued Ultrahuman and SVTronics Inc. for patent infringement in the U.S. District Court for the Eastern District of Texas, alleging Ultrahuman's Ring Pro infringes its design and utility patents. Oura seeks injunctive relief and damages, including treble damages for willful infringement. This follows an earlier ITC ruling excluding Ultrahuman's Ring Air from the U.S. market.

HighAI 9/10

Oura IPO Postponed as Kalshi Traders Rethink 2026 Debuts

Oura, a sleep-tracking ring company, postponed its IPO despite a 99% predicted chance, citing market conditions. It reported $1.2B revenue and $60.8M net income for 2026. The delay reflects broader IPO market slowdown, with only 30 U.S. IPOs in Q3 2026, down from 64 in 2025.

MedAI 8/10

Smart Ring Maker Oura Delays Nasdaq IPO, Citing Market Uncertainty

Oura, a smart ring maker, delayed its Nasdaq IPO citing market uncertainty. The company aimed to sell 50M shares, raising up to $2.2B at a $15B valuation. Oura reported strong earnings, with $907.8M revenue and $23.5M pretax profit in fiscal 2025. The delay follows a lawsuit alleging false advertising, but the company denies this influenced the decision.

Low

Oura postpones its $2.2bn IPO, citing market uncertainty

Oura postponed its $2.2bn IPO, citing market uncertainty despite strong demand. It planned to sell 50M shares at $40-$44 each. The company is profitable, with 5.7M paid members and expects 90% revenue growth in 2026. Four companies postponed IPOs in the same week, according to Renaissance Capital.